期刊文献+

不同中西药组合方案对实验性兔髂动脉硬化模型CRP水平的影响 被引量:1

下载PDF
导出
摘要 目的:探讨不同中西药组合通过干预炎症反应而延缓AS病变的疗效,为中西医结合防治AS的研究提供依据。方法:4只普通饲料喂养大鼠作为空白对照组;66只经高脂饲料喂养大鼠,经模型评价,均符合标准。分出6只作为模型对照组,将其余实验模型随机分为10组,每组按疗程给予相应的受试药物,15日后颈动脉采血,采用固相酶联免疫吸附法(ELISA法)测血清C-反应蛋白(CRP)水平。结果:采用ELISA检测结果显示,各治疗组兔血清与模型组相比,CRP指标水平明显降低(P<0.01或P<0.05),各治疗组之间比较有统计学意义(P<0.01或P<0.05)。结论:肝素、阿司匹林和葛根素、疏血通组合方案对实验性兔髂动脉硬化模型CRP水平的降低能取得较好效果。
出处 《辽宁中医杂志》 CAS 2013年第3期583-584,共2页 Liaoning Journal of Traditional Chinese Medicine
基金 黑龙江省教育厅课题(12511531)
  • 相关文献

参考文献3

  • 1魏群,陈芳,沈晓君,魏宴.葛根素对兔动脉粥样硬化炎症因子的影响[J].中国老年学杂志,2011,31(18):3541-3543. 被引量:15
  • 2Inoue N.Vascular C-reactive protein in the pathogenesis ofcoronary ar-tery disease:role of vascular inflammation andoxidative stress[J].Cardiovasc Hematol Disord Drug Targets,2006,6(4):227-231.
  • 3Paul A,Ko KW,Li L,et al.C-reactive protein accelerates the pro-gression of atherosclerosis in apolipoprotein E-deficient mice[J].Cir-culation,2004,109(5):647-655.

二级参考文献13

  • 1Tavridou A, Kaklamanis L, Papalois A ,et al. EP2306 [ 2-(4-Biphenyl)-4- methyl -octahy dro- 1,4-benzoxazin-2-ol, hydrobromide ], a novel squalene synthase inhibitor, reduces atheroselerosis in the cholesterol-fed rabbit [ J ]. J Pharmacol Exper Therapeu,2008:323 ( 3 ) :794-804.
  • 2Zhou, MD, Geoff Werstuck, Sarka Lhotak, et al. Association of multiple cellular stress pathways with accelerated atherosclerosis in hyperhomocysteinemic apolipoprotein E-deficient mice[J]. Circulation, 2004;13 (7) : 207-13.
  • 3Nonaka H, Tsujino T, Taurine YW, et al.Prevents the decrease in expression and secretion of extracellular superoxide dismutase induced by homocysteine amelioration of homocysteine-induced endoplasmic reticulum stress by taurine[J].Circulation. 2001 : 104 ( 11 ):1165-70.
  • 4Suhara T, Fukuo K, Yasuda O, et al. Homocysteine enhances endothelial apoptosis via npregulation of Fas-mediated pathways[J]. Hypertension, 2004 ;43 ( 6 ) : 1208-13.
  • 5Singh SK, Suresh MV, Voleti B, et al. The connection between C-reactive protein and atherosclerosis ( J 1- Ann Med,2008 ;40 ( 2 ) : 110 -20.
  • 6Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality : an individual participant meta-analysis[J]. Lancet, 2010 ; 375 ( 9709 ) : 132 -40.
  • 7Haghjooyjavanmarda S, Nematbakhsha M, Monajemia A, et al. Von Willebrand factor, C-reactive protein, nitric oxide, and vascular endothelial growth factor in a dietary reversal model of hypercholesterolemia in rabbit [J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub,2008; 152 ( 1 ) :91-5.
  • 8Ridker PM, Cannon CP, Morrow D, et al.C-reactive protein levels and outcomes after statin therapy[J]. N Engl J Med ,2005 ;352 (1) :20-8.
  • 9Nissen SE, Tuzcu EM, Schoenhagen P,et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease[ J]. N Engl J Med, 2005 ;352( 1 ) :29-38.
  • 10Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein [J]. N Engl J Med,2008 ;359(21 ) :2195-207.

共引文献14

同被引文献22

引证文献1

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部